Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen

Bank of New York Mellon

British American Tobacco

GlaxoSmithKline

Imperial Brands PLC

Intel

Lockheed Martin

Altria

Merck

Roche Holding AG

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The January 2021 Heat Map

Cara Therapeutics

Canopy Growth

GrowGeneration Corp

These 6 cannabis stocks show promise in the medical and recreational ends of the burgeoning marijuana sector, set to grow even more in 2021. The post 6 Cannabis Stocks to Buy as the U.S. Softens Its Stance appeared first on InvestorPlace.

6 Cannabis Stocks to Buy as the U.S. Softens Its Stance

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi: Information concerning the total number of voting rights and shares - November 2020

Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback

AstraZeneca

Moderna

Pfizer

The challenges for two big drugmakers could translate to opportunities for their rivals in the COVID-19 vaccine race.

Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna

Health-care stocks are in focus after Pfizer began shipments in the U.S. of its Covid vaccine and the first vaccinations were given this week.

One health-care stock looks like a buy as Pfizer begins Covid vaccine rollout, market analyst says

Sanofi renews partnership with the WHO to fight Neglected Tropical Diseases and eliminate sleeping sickness before 2030 

The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study.

Sanofi and GlaxoSmithKline Delay COVID-19 Vaccine Program Due to Poor Immune Response in Older Adults

Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an improved antigen formulation.

Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate

Sanofi and GlaxoSmithKline pushed back the timeline for rolling out their coronavirus vaccine after finding it didn't work as well in older people. The drugmakers' Friday announcement created a roadblock in its race to produce a safe and effective inoculation for COVID-19 — the same day Health and Human Services Secretary Alex Azar said the.

Sanofi, GlaxoSmithKline delay COVID-19 vaccine rollout to late 2021

Sanofi and GlaxoSmithKline, the French and British pharmaceutical groups, said on Friday that they would delay the launch of their joint coronavirus vaccine until the end of 2021.

Sanofi/GSK vaccine setback adds to uncertainty ahead of Europe's mass inoculation campaigns

The vaccine will not be available until the last quarter of 2021.

Sanofi-GSK Covid-19 Vaccine Delayed After Trials Show Poor Immune Response In Elderly

A COVID-19 vaccine being developed by two of the world's biggest vaccine makers, GlaxoSmithKline and Sanofi, has been delayed after it didn't show a strong enough response in older people. GlaxoSmithKline and Sanofi are now expecting potential distribution of their shot in the final months of 2021. Initially, they had expected the vaccine to be available from mid-2021.

GSK and Sanofi delay the expected rollout of their COVID-19 vaccine until late 2021 because of an insufficient response in older people. The US has ordered 100 million doses.

Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in the global fight against the pandemic.

Sanofi and GSK delay COVID-19 vaccine, marking setback for global fight

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) on Friday reported a delay in their COVID-19 vaccine program as interim results from Phase 1 and 2 trials indicate a low immune response in older adults. What Happened: The drugmakers said in a statement that early-stage vaccine trials indicate a low immune response in older adults — most likely caused by an insufficient concentration of the antigen.

GSK-Sanofi COVID-19 Vaccine Shows Insufficient Immunity, Late-Stage Trials Delayed

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

Novavax

There are plenty of catalysts on the horizon for these investments -- and a healthy dose of risk.

3 Best Biotech Stocks of 2020: Are They Buys Now?

Sanofi Is Set To Soar After COVID-19 Vaccine News

Sanofi pioneers sustainable finance in the pharmaceutical industry with the signing of its two first sustainability-linked revolving credit facilities

This is a joint press release by Sanofi ("Sanofi") and Kiadis Pharma N.V. ("Kiadis"), pursuant to the provisions of Section 4, paragraph 3 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft) and Section 17 paragraph 1 of the European Market Abuse Regulation (596/2014), in connection with the intended public offer by Sanofi for all the issued and outstanding ordinary shares in the capital of Kiadis (the "Offer"). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of an offer memorandum (the "Offer Document") approved by the Dutch Authority for the Financial Markets (Autoriteit Financiële Markten) (the "AFM") and recognized by the Belgian Authority for the Financial Markets (Autoriteit voor Financiële Diensten en Markten) (the ''FSMA''). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan or in any other jurisdiction in which such release, publication or distribution would be unlawful.

Sanofi and Kiadis satisfy competition condition related to the tender offer

BioNTech SE

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure appeared first on InvestorPlace.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

Sanofi Has A Promising Earnings Outlook

CRISPR Therapeutics

Editas Medicine

Eli Lilly

Novo Nordisk

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

How You Can Profit From the Best-Managed Drugmaker on Earth

Orange

UBS Group AG

Value investors should take the time to have a look at the following securities, as their share prices are trading below the Peter Lynch earnings line, indicating possible value opportunities.

News for Sanofi Stock (SNY)